EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study

Catherine M Bjerum iD, Benjamin G Koudou, Allassane F Ouattara, Daphne Lew, Charles W Goss, Pascal T Gabo, Christopher L King, Peter U Fischer, Gary J Weil, Philip J Budge

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011633 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Catherine M Bjerum und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Elephantiasis, Filarial, Filaricides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Bill and Melinda Gates Foundation, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Moxidectin is a macrocyclic lactone registered for the treatment of human onchocerciasis. The drug has a good safety profile, large volume of distribution and a long elimination half-life. This paper reports tolerability data from the first use of moxidectin in persons with Wuchereria bancrofti infection.

Methods

In this randomized, open-label, masked-observer superiority trial, adults with Wuchereria bancrofti microfilaremia in Côte d’Ivoire were randomized to 1 of 4 treatment arms: ivermectin + albendazole (IA), moxidectin + albendazole (MoxA), ivermectin + diethylcarbamazine (DEC) + albendazole (IDA), or moxidectin + DEC + albendazole (MoxDA). As part of a larger efficacy trial, all participants were closely monitored for 7 days after treatment.

Results

One hundred sixty-four individuals were treated, and monitored for treatment emergent adverse events (TEAE). Eighty-seven participants (53%) experienced one or more mild (grade 1) or moderate (grade 2) TEAE. Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA). There were no serious adverse events. There were no significant differences in frequency or types of TEAE between treatment groups (IA = 22/41 (53%), MoxA = 24/40 (60%), IDA = 18/41 (44%), MoxDA = 15/42 (36%), p = 0.530). Fifty-nine participants (36%) had multiple TEAE, and 8.5% had a one or more grade 2 (moderate) TEAE. Grade 2 TEAE were more frequent after triple drug treatments (IDA, 14.6%; MoxDA, 9.5%) than after two-drug treatments (IA, 7.3%; MoxA, 2.5%). There was no difference in TEAEs based on baseline Mf counts (OR 0.69 (0.33, 1.43), p-value 0.319).

Conclusion

All treatment regimens were well tolerated. We observed no difference in safety parameters between regimens that contained ivermectin or moxidectin.

Trial registration

Clinicaltrials.gov, NCT04410406 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elephantiasis, FilarialFilaricidesAdultAnimalsHumansIvermectinAlbendazoleCote d'IvoireWuchereria bancroftiDrug Therapy, CombinationDiethylcarbamazineMacrolides

Substanzen

IvermectinAlbendazoleDiethylcarbamazineFilaricidesmoxidectinMacrolides

Autor:innen und Institutionen

  • Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
  • Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
  • Centre Suisse de Recherche Scientifique en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Centre Hospitalier Régional d'Agboville, Agboville, Côte d'Ivoire.
  • Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, United States of America.

ORCID-Profile: Catherine M Bjerum

Förderung

  • NIAID NIH HHS
  • Bill and Melinda Gates Foundation
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Bjerum, C. M., Koudou, B. G., Ouattara, A. F., Lew, D., Goss, C. W., Gabo, P. T., King, C. L., Fischer, P. U., Weil, G. J., & Budge, P. J. (2023). Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011633

Vancouver

Bjerum CM, Koudou BG, Ouattara AF, Lew D, Goss CW, Gabo PT, et al. Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011633

BibTeX
@article{Bjerum2023,
  author = {Bjerum, Catherine M and Koudou, Benjamin G and Ouattara, Allassane F and Lew, Daphne and Goss, Charles W and Gabo, Pascal T and King, Christopher L and Fischer, Peter U and Weil, Gary J and Budge, Philip J},
  title = {Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011633}
}
Kostenlos starten →